Sellas Life Sciences Group (ehemals Galena Biopharma) (Seite 224)
eröffnet am 30.10.12 22:43:19 von
neuester Beitrag 17.05.24 07:21:04 von
neuester Beitrag 17.05.24 07:21:04 von
Beiträge: 2.942
ID: 1.177.530
ID: 1.177.530
Aufrufe heute: 1
Gesamt: 345.967
Gesamt: 345.967
Aktive User: 0
ISIN: US81642T2096 · WKN: A2PU3T · Symbol: SLS
1,4600
USD
-0,68 %
-0,0100 USD
Letzter Kurs 02:00:00 Nasdaq
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,25 | +63,04 | |
| 0,8000 | +45,45 | |
| 1,0000 | +42,86 | |
| 6,2500 | +24,75 | |
| 0,8200 | +15,49 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 114,60 | -13,61 | |
| 23,700 | -19,52 | |
| 28,60 | -24,06 | |
| 1,3500 | -25,62 | |
| 0,7800 | -29,73 |
Beitrag zu dieser Diskussion schreiben
Feedback
ahhh,...ich glaub kiry hat sich welche geholt,...Kurs steigt schnell!
Antwort auf Beitrag Nr.: 48.855.005 von kirroyal am 22.01.15 18:46:37DANKE !!
Maxim Group set a $7.00 target price on Galena Biopharma (NASDAQ:GALE) in a report issued on Friday. The firm currently has a a buy rating on the stock.
Galena Biopharma (NASDAQ:GALE) traded up 0.57% during mid-day trading on Friday, hitting $1.76. 1,154,231 shares of the company’s stock traded hands. Galena Biopharma has a 52 week low of $1.43 and a 52 week high of $7.15. The stock’s 50-day moving average is $1.63 and its 200-day moving average is $2.14. The company’s market cap is $213.8 million.
Galena Biopharma (NASDAQ:GALE) last issued its quarterly earnings data on Monday, November 3rd. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.06. The company had revenue of $1.60 million for the quarter, compared to the consensus estimate of $2.66 million. The company’s revenue for the quarter was up 38.5% on a year-over-year basis.
A number of other analysts have also recently weighed in on GALE. Analysts at MLV & Co
raised their price target on shares of Galena Biopharma from $3.00 to $5.00 and gave the company a buy rating in a research note on Thursday, November 20th. Analysts at Roth Capital reiterated a positive rating on shares of Galena Biopharma in a research note on Tuesday, November 18th. Finally, analysts at Cantor Fitzgerald reiterated a sell rating and set a $2.00 price target (down previously from $2.25) on shares of Galena Biopharma in a research note on Tuesday, November 4th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The company presently has an average rating of Buy and a consensus price target of $5.83.
Galena Biopharma, Inc (NASDAQ:GALE), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics.
http://tickerreport.com/banking-finance/389424/galena-biopha…
Galena Biopharma (NASDAQ:GALE) traded up 0.57% during mid-day trading on Friday, hitting $1.76. 1,154,231 shares of the company’s stock traded hands. Galena Biopharma has a 52 week low of $1.43 and a 52 week high of $7.15. The stock’s 50-day moving average is $1.63 and its 200-day moving average is $2.14. The company’s market cap is $213.8 million.
Galena Biopharma (NASDAQ:GALE) last issued its quarterly earnings data on Monday, November 3rd. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.06. The company had revenue of $1.60 million for the quarter, compared to the consensus estimate of $2.66 million. The company’s revenue for the quarter was up 38.5% on a year-over-year basis.
A number of other analysts have also recently weighed in on GALE. Analysts at MLV & Co
raised their price target on shares of Galena Biopharma from $3.00 to $5.00 and gave the company a buy rating in a research note on Thursday, November 20th. Analysts at Roth Capital reiterated a positive rating on shares of Galena Biopharma in a research note on Tuesday, November 18th. Finally, analysts at Cantor Fitzgerald reiterated a sell rating and set a $2.00 price target (down previously from $2.25) on shares of Galena Biopharma in a research note on Tuesday, November 4th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The company presently has an average rating of Buy and a consensus price target of $5.83.
Galena Biopharma, Inc (NASDAQ:GALE), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics.
http://tickerreport.com/banking-finance/389424/galena-biopha…
Kann jemand einen Tageschart einfügen?
Trading Spotlight
Hey,...scheint einen Boden zu geben heute...
Antwort auf Beitrag Nr.: 48.842.498 von patg am 21.01.15 20:09:41
GALE Earnings Date
Earnings announcement* for GALE: Mar 16, 2015
Galena Biopharma, Inc. is estimated to report earnings on 03/16/2015. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.12. The reported EPS for the same quarter last year was $-0.13.
http://www.nasdaq.com/earnings/report/gale
GALE Earnings Date
Earnings announcement* for GALE: Mar 16, 2015
Galena Biopharma, Inc. is estimated to report earnings on 03/16/2015. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.12. The reported EPS for the same quarter last year was $-0.13.
http://www.nasdaq.com/earnings/report/gale
Antwort auf Beitrag Nr.: 48.842.456 von lunatics am 21.01.15 20:06:02Wann gibt es denn Zahlen zum 4. Quartal?
Ich habe auf der Homepage nichts gefunden....
Ich habe auf der Homepage nichts gefunden....
Ich verstehe Deine Frage nicht...
Ich finde GALE eine interessante Firma. Nein, ich bin derzeit nicht re-investiert weil ich der Meinung bin dass der Zeitpunkt zum Kaufen für mich nicht optimal ist.
Ich finde GALE eine interessante Firma. Nein, ich bin derzeit nicht re-investiert weil ich der Meinung bin dass der Zeitpunkt zum Kaufen für mich nicht optimal ist.
Durchsuchen
